Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 1/2019

Open Access 01-01-2019 | Review

Metabolites of prostaglandin synthases as potential biomarkers of Lyme disease severity and symptom resolution

Authors: Alicia Caroline Jarosz, Alaa Badawi

Published in: Inflammation Research | Issue 1/2019

Login to get access

Abstract

Background

Lyme disease or Lyme borreliosis (LB) is the commonest vector-borne disease in the North America. It is an inflammatory disease caused by the bacterium Borrelia burgdorferi. The role of the inflammatory processes mediated by prostaglandins (PGs), thromboxanes and leukotrienes (LTs) in LB severity and symptoms resolution is yet to be elucidated.

Objectives

We aim to systematically review and evaluate the role of PGs and related lipid mediators in the induction and resolution of inflammation in LB.

Methods

We conducted a comprehensive search in PubMed, Ovid MEDLINE(R), Embase and Embase Classic to identify cell-culture, animal and human studies reporting the changes in PGs and related lipid mediators of inflammation during the course of LB.

Results

We identified 18 studies to be included into this systematic review. The selected reports consisted of seven cell-culture studies, seven animal studies, and four human studies (from three patient populations). Results from cell-culture and animal studies suggest that PGs and other lipid mediators of inflammation are elevated in LB and may contribute to disease development. The limited number of human studies showed that subjects with Lyme meningitis, Lyme arthritis (LA) and antibiotic-refractory LA had increased levels of an array of PGs and lipid mediators (e.g., LTB4, 8-isoPGF2α, and phospholipases A2 activity). Levels of these markers were significantly reduced following the treatment with antibiotics or non-steroidal anti-inflammatory drugs.

Conclusion

Dysregulation of prostaglandins and related lipid mediators may play a role in the etiology of LB and persistence of inflammation that may lead to long-term complications. Further investigation into the precise levels of a wide range of PGs and related factors is critical as it may propose novel markers that can be used for early diagnosis.
Appendix
Available only for authorised users
Literature
1.
Radolf JD, Caimano MJ, Stevenson B, Hu LT. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol. 2012;10(2):87–99.CrossRef
2.
3.
4.
Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, et al. Lyme disease testing by large commercial laboratories in the United. Clin Infect Dis. 2014;59(5):676–81.CrossRef
5.
Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med. 2003;348(24):2472–4.CrossRef
6.
Wormser GP. Clinical practice. Early Lyme disease. N Engl J Med. 2006;354(26):2794–801.CrossRef
7.
8.
Centers for Disease Control and Prevention. Three sudden cardiac deaths associated with Lyme carditis—United States, November 2012–July 2013. Morb Mortal Wkly Rep. 2013;62(49):993–6.
9.
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089–134.CrossRef
10.
Ogden NH, Lindsay LR, Morshed M, Sockett PN, Artsob H. The emergence of Lyme disease in Canada. Can Med Assoc J. 2009;180(12):1221–4.CrossRef
11.
12.
Bockenstedt LK, Wormser GP. Review: unraveling Lyme disease. Arthritis Rheumatol. 2014;66(9):2313–23.CrossRef
13.
Badawi A. The potential of omics technologies in Lyme disease biomarker discovery and early detection. Infect Dis Therap. 2016;6:85–102.CrossRef
14.
Tam VC. Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections. Semin Immunol. 2013;25(3):240–8.CrossRef
15.
Beutler B. Innate immunity: an overview. Mol Immunol. 2004;40(12):845–59.CrossRef
16.
Duray PH. Histopathology of clinical phases of human Lyme disease. Rheum Dis Clin N Am. 1989;15(4):691–710.
17.
Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol. 2002;2(10):787–95.CrossRef
18.
Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med. 2011;365(19):1812–23.CrossRef
19.
Buczynski MW, Dumlao DS, Dennis EA. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res. 2009;50(6):1015–38.CrossRef
20.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349–61.CrossRef
21.
Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol. 2004;4(2):143–52.CrossRef
22.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.CrossRef
23.
Cohen A. Comparison of correlated correlations. Stat Med. 1989;8(12):1485–95.CrossRef
24.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRef
25.
Rasley A, Anguita J, Marriott I. Borrelia burgdorferi induces inflammatory mediator production by murine microglia. J Neuroimmunol. 2002;130(1–2):22–31.CrossRef
26.
Rasley A, Marriott I, Halberstadt CR, Bost KL, Anguita J. Substance P augments Borrelia burgdorferi-induced prostaglandin E2 production by murine microglia. J Immunol. 2004;172(9):5707–13.CrossRef
27.
Ramesh G, Borda JT, Dufour J, et al. Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol. 2008;173(5):1415–27.CrossRef
28.
Ramesh G, Martinez AN, Martin DS, Philipp MT. Effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in glial and neuronal cells of the central nervous system. J Neuroinflamm. 2017;14(1):28.CrossRef
29.
Blaho VA, Buczynski MW, Dennis EA, Brown CR. Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17. J Immunol. 2009;183(9):5644–53.CrossRef
30.
Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. Annu Rev Biochem. 1994;63:383–417.CrossRef
31.
Gerstmeier J, Weinigel C, Rummler S, Radmark O, Werz O, Garscha U. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes. FASEB J. 2016;30(1):276–85.CrossRef
32.
Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007;32(7):332–41.CrossRef
33.
Zhang Y, Olson RM, Brown CR. Macrophage LTB4 drives efficient phagocytosis of Borrelia burgdorferi via BLT1 or BLT2. J Lipid Res. 2017;58(3):494–503.CrossRef
34.
Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2–3):123–34.CrossRef
35.
Mancuso P, Lewis C, Serezani CH, Goel D, Peters-Golden M. Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. Infect Immun. 2010;78(5):2264–71.CrossRef
36.
Mancuso P, Standiford TJ, Marshall T, Peters-Golden M. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. Infect Immun. 1998;66(11):5140–6.PubMedPubMedCentral
37.
Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633):620–4.CrossRef
38.
Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192(3):421–32.CrossRef
39.
Singh SK, Morbach H, Nanki T, Faber C, Baar V, Girschick HJ. Differential expression of matrix metalloproteinases and cyclooxygenases in synovial cells exposed to Borrelia burgdorferi. Inflamm Res. 2004;53(12):689–96.CrossRef
40.
Anguita J, Samanta S, Ananthanarayanan SK, et al. Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis. FEMS Immunol Med Microbiol. 2002;34(3):187–91.CrossRef
41.
Glasner J, Blum H, Wehner V, et al. A small molecule alpha 4 beta 1 antagonist prevents development of murine Lyme arthritis without affecting protective immunity. J Immunol. 2005;175(7):4724–34.CrossRef
42.
Blaho VA, Mitchell WJ, Brown CR. Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease. Arthritis Rheum. 2008;58(5):1485–95.CrossRef
43.
Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J Biol Chem. 2009;284(32):21599–612.CrossRef
44.
Blaho VA, Zhang Y, Hughes-Hanks JM, Brown CR. 5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis. J Immunol. 2011;186(5):3076–84.CrossRef
45.
Lasky CE, Olson RM, Brown CR. Macrophage polarization during murine Lyme borreliosis. Infect Immun. 2015;83(7):2627–35.CrossRef
46.
Dumlao DS, Cunningham AM, Wax LE, et al. Dietary fish oil substitution alters the eicosanoid profile in ankle joints of mice during Lyme infection. J Nutr. 2012;142(8):1582–9.CrossRef
47.
Luczaj W, Moniuszko A, Rusak M, Zajkowska J, Pancewicz S, Skrzydlewska E. Peroxidative metabolism of arachidonic acid in the course of Lyme arthritis. Ann Agric Environ Med. 2015;22(3):433–7.CrossRef
48.
Luczaj W, Moniuszko A, Rusak M, Pancewicz S, Zajkowska J, Skrzydlewska E. Lipid peroxidation products as potential bioindicators of Lyme arthritis. Eur J Clin Microbiol Infect Dis. 2011;30(3):415–22.CrossRef
49.
Mayatepek E, Hassler D, Maiwald M. Enhanced levels of leukotriene B(4) in synovial fluid in Lyme disease. Mediators Inflamm. 1993;2(3):225–8.CrossRef
50.
Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87(23):9383–7CrossRef
51.
Molins CR, Ashton LV, Wormser GP, et al. Development of a metabolic biosignature for detection of early Lyme disease. Clin Infect Dis. 2015;60(12):1767–75.CrossRef
52.
Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med. 2004;10(4):411–5.CrossRef
53.
Paccani SR, Patrussi L, Ulivieri C, Masferrer JL, D’Elios MM, Baldari CT. Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling. Blood. 2005;105(5):2042–8.CrossRef
54.
Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem. 2000;275(31):23627–35.CrossRef
55.
Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120(15):e60–72.CrossRef
56.
Smith BG, Cruz AI Jr, Milewski MD, Shapiro ED. Lyme disease and the orthopaedic implications of lyme arthritis. J Am Acad Orthop Surg. 2011;19(2):91–100.CrossRef
57.
Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort. J Rheumatol. 2010;37(5):1049–55.CrossRef
58.
Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63(6):525–34.CrossRef
59.
el Attar TM, Lin HS. Effect of vitamin C and vitamin E on prostaglandin synthesis by fibroblasts and squamous carcinoma cells. Prostaglandins Leukot Essent Fatty Acids. 1992;47(4):253–7.CrossRef
60.
61.
Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA. 2003;100(4):1751–6.CrossRef
62.
Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009;206(1):15–23.CrossRef
63.
Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory–pro-resolving mediators and their receptors. Curr Top Med Chem. 2011;11(6):629–47.CrossRef
64.
Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006;6(4):414–20.CrossRef
Metadata
Title
Metabolites of prostaglandin synthases as potential biomarkers of Lyme disease severity and symptom resolution
Authors
Alicia Caroline Jarosz
Alaa Badawi
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 1/2019
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-018-1180-5

Other articles of this Issue 1/2019

Inflammation Research 1/2019 Go to the issue

Review

A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future

Review

A review of inflammatory mechanism in airway diseases

Short Communication

Altered regulation of the T-cell system in patients with CRPS

Original Research Paper

CD8+ T cell/IL-33/ILC2 axis exacerbates the liver injury in Con A-induced hepatitis in T cell-transferred Rag2-deficient mice

Review

Cross talk between natural killer cells and mast cells in tumor angiogenesis

Review

C-reactive protein as a biomarker of severe H1N1 influenza

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits